人肝病进展中的表观遗传异质性热点
研究对31例肝病患者多个肝区域进行全基因组DNA甲基化、拷贝数和基因表达谱分析,发现跨患者保守的表观遗传异质性热点,其与基因表达异质性升高相关,肝硬化区域可分两群,热点富集肝功能核心基因和抑癌基因,并与临床结局指标相关。
要点
- 表观遗传异质性在肝病早期即出现,靶向肝硬化和肝细胞癌进展与启动的关键通路。
- 肝硬化区域由两群组成:一群仅表观遗传变异,另一群为表观遗传与拷贝数变异协同。
- 表观遗传异质性热点富集HNF1A、RASSF1A、ACSL1、ACSL5、MAT1A和ELFN1等基因,并与临床结局指标相关。
核心结论
- 大量表观遗传异质性在肝病发展早期出现,靶向肝硬化和肝细胞癌进展与启动的关键通路。
- 整合表观遗传和转录异质性可揭示肝细胞癌发生的候选表观遗传调控因子。
研究设计与样本
- 对31例肝病患者的多个肝区域进行全基因组DNA甲基化、拷贝数和基因表达谱分析,以检查其交互作用并界定各过程对肝病进展的单独和联合贡献。
主要发现
- 鉴定出跨患者保守的表观遗传异质性热点,表观遗传异质性升高与基因表达异质性增加相关。
- 肝硬化区域包含2个不同群:一群仅表观遗传变异,另一群表观遗传与拷贝数变异协同。
- 表观遗传异质性热点富集肝功能核心基因(如HNF1A)和已知抑癌基因(如RASSF1A)。
- 热点涵盖ACSL1、ACSL5、MAT1A和ELFN1等基因,这些基因在功能筛选中具有表型效应,支持其与肝细胞癌发生的相关性。
- 表观遗传异质性热点与临床结局指标相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Disruption of the epigenome is a hallmark of human disease, including liver cirrhosis and HCC. While genetic heterogeneity is an established effector of pathologic phenotypes, epigenetic heterogeneity is less well understood. Environmental exposures alter the liver-specific DNA methylation landscape and influence the onset of liver cancer. Given that currently available treatments are unable to target frequently mutated genes in HCC, there is an unmet need for novel therapeutics to prevent or reverse liver damage leading to hepatic tumorigenesis, which the epigenome may provide. APPROACH AND RESULTS: We performed genome-wide profiling of DNA methylation, copy number, and gene expression from multiple liver regions from 31 patients with liver disease to examine their crosstalk and define the individual and combinatorial contributions of these processes to liver disease progression. We identified epigenetic heterogeneity hotspots that are conserved across patients. Elevated epigenetic heterogeneity is associated with increased gene expression heterogeneity. Cirrhotic regions comprise 2 distinct cohorts-one exclusively epigenetic, and the other where epigenetic and copy number variations collaborate. Epigenetic heterogeneity hotspots are enriched for genes central to liver function (eg, HNF1A ) and known tumor suppressors (eg, RASSF1A ). These hotspots encompass genes including ACSL1 , ACSL5 , MAT1A , and ELFN1 , which have phenotypic effects in functional screens, supporting their relevance to hepatocarcinogenesis. Moreover, epigenetic heterogeneity hotspots are linked to clinical measures of outcome. CONCLUSIONS: Substantial epigenetic heterogeneity arises early in liver disease development, targeting key pathways in the progression and initiation of both cirrhosis and HCC. Integration of epigenetic and transcriptional heterogeneity unveils putative epigenetic regulators of hepatocarcinogenesis.
引用
- Hlady RA, Zhao X, El Khoury LY, et al. Epigenetic heterogeneity hotspots in human liver disease progression. Hepatology. 2024. PMID: 39028883. doi:10.1097/HEP.0000000000001023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。